menu
    • menu

    Find Roflumilast manufacturers, exporters & distributors on PharmaCompass

    Interquim Roflumilast New

    Virtual Booth

    Contact Supplier

    M2i Group Roflumilast

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    26

    API Suppliers

    API Suppliers

    13

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    6

    EU WC

    EU WC

    4

    KDMF

    KDMF

    10

    NDC API

    NDC API

    0

    VMF

    NDC API

    17

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 161,827

    MARKET PLACE

    13

    API

    1

    FDF

    6INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    47

    FDF Dossiers

    FDF Dossiers

    23

    FDA Orange Book

    FDA (Orange Book)

    14

    Europe

    Europe

    2

    Canada

    Canada

    0

    Australia

    Australia

    1

    South Africa

    South Africa

    7

    Listed Dossiers

    Listed Dossiers

    84DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    5

    Others

    PATENTS & EXCLUSIVITIES

    45

    US Patents

    4

    US Exclusivities

    4

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    93

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    191,817,472

    Annual Reports

    1,443

    Finished Drug Prices

    Listed Dossiers

    78 RELATED EXCIPIENT COMPANIES

    130EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 162401-32-3, Daxas, 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide, Daliresp, By217, Byk20869
    Molecular Formula
    C17H14Cl2F2N2O3
    Molecular Weight
    403.2  g/mol
    InChI Key
    MNDBXUUTURYVHR-UHFFFAOYSA-N
    FDA UNII
    0P6C6ZOP5U
    Roflumilast
    Roflumilast is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.
    Roflumilast is a Phosphodiesterase 4 Inhibitor. The mechanism of action of roflumilast is as a Phosphodiesterase 4 Inhibitor.
    1 2D Structure

    Roflumilast

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
    2.1.2 InChI
    InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
    2.1.3 InChI Key
    MNDBXUUTURYVHR-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    0P6C6ZOP5U
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-di-chloropyrid-4-yl)benzamide

    2. Daliresp

    2.3.2 Depositor-Supplied Synonyms

    1. 162401-32-3

    2. Daxas

    3. 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

    4. Daliresp

    5. By217

    6. Byk20869

    7. By-217

    8. B9302-107

    9. By 217

    10. 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide

    11. Roflumilast (daxas)

    12. Benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-

    13. Byk-20869

    14. 0p6c6zop5u

    15. Chembl193240

    16. Chebi:47657

    17. 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

    18. Byk 20869

    19. Mfcd00938270

    20. B 9302-107

    21. Rof

    22. Libertek

    23. Roflumilast [usan]

    24. B-9302-107

    25. Roflumilast [usan:inn]

    26. Unii-0p6c6zop5u

    27. Roflumilastum

    28. Roflumilast (jan/usan/inn)

    29. Apta-2217

    30. 1xmu

    31. 1xoq

    32. Daliresp (tn)

    33. Roflumilast- Bio-x

    34. 3g4l

    35. Roflumilast [mi]

    36. Roflumilast [inn]

    37. Roflumilast [jan]

    38. 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-di-chloropyrid-4-yl)benzamide

    39. Roflumilast [vandf]

    40. Roflumilast [mart.]

    41. Schembl19158

    42. Roflumilast [who-dd]

    43. Mls006010074

    44. Roflumilast [ema Epar]

    45. Gtpl6962

    46. Dtxsid8044123

    47. Apta 2217

    48. Bdbm14774

    49. Roflumilast, >=98% (hplc)

    50. Amy4219

    51. Ex-a059

    52. Roflumilast [orange Book]

    53. Hms3655p21

    54. Hms3748c19

    55. Hms3884f09

    56. Zinc592419

    57. Act02619

    58. Bcp03736

    59. S2131

    60. Arq-151/zoryve (roflumilast Cream)

    61. Akos005146309

    62. Am84550

    63. Ccg-268678

    64. Cs-0963

    65. Db01656

    66. Pb29130

    67. Ncgc00346566-01

    68. Ncgc00346566-09

    69. Ac-23383

    70. As-14120

    71. Br164364

    72. Hy-15455

    73. Smr002530074

    74. Sy008710

    75. Bcp0726000146

    76. Ft-0660846

    77. R0193

    78. Sw220196-1

    79. A24672

    80. D05744

    81. Ab01565852_02

    82. 401r323

    83. Q693482

    84. J-510858

    85. Brd-k03194791-001-02-2

    86. 3- Cyclo-propylmethoxy-4-difluoromethoxy-n- [3, 5-di-chloropyrid-4-yl]- Benzamid

    87. Benzamide, 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-

    88. N-(3,5-dichloropyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 403.2 g/mol
    Molecular Formula C17H14Cl2F2N2O3
    XLogP34.6
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count7
    Exact Mass402.0349540 g/mol
    Monoisotopic Mass402.0349540 g/mol
    Topological Polar Surface Area60.4 Ų
    Heavy Atom Count26
    Formal Charge0
    Complexity475
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameDaliresp
    PubMed HealthRoflumilast (By mouth)
    Drug ClassesRespiratory Agent
    Drug LabelThe active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylm...
    Active IngredientRoflumilast
    Dosage FormTablet
    RouteOral
    Strength500mcg
    Market StatusPrescription
    CompanyForest Res Inst

    2 of 2  
    Drug NameDaliresp
    PubMed HealthRoflumilast (By mouth)
    Drug ClassesRespiratory Agent
    Drug LabelThe active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylm...
    Active IngredientRoflumilast
    Dosage FormTablet
    RouteOral
    Strength500mcg
    Market StatusPrescription
    CompanyForest Res Inst

    4.2 Drug Indication

    Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

    FDA Label

    Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

    Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

    Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

    Chronic obstructive pulmonary disease

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Roflumilast (and its active metabolite, roflumilast N-oxide) increases cyclic adenosine-3, 5-monophosphate (cAMP) in lung cells by inhibiting PDE4. Increased cAMP activates PKA, which inactivates transcription factors involved in inflammation. Romflumilast also decreases the amount of sputum neutrophils and eosinophils in COPD patients.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    ROFLUMILAST
    5.2.2 FDA UNII
    0P6C6ZOP5U
    5.2.3 Pharmacological Classes
    Phosphodiesterase 4 Inhibitors [MoA]; Phosphodiesterase 4 Inhibitor [EPC]
    5.3 ATC Code

    R03DX07

    R03DX08

    R03DX07

    R03DX07

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    R - Respiratory system

    R03 - Drugs for obstructive airway diseases

    R03D - Other systemic drugs for obstructive airway diseases

    R03DX - Other systemic drugs for obstructive airway diseases

    R03DX07 - Roflumilast

    5.4 Absorption, Distribution and Excretion

    Absorption

    After a 500mcg dose, the bioavailability of roflumilast is about 80%. In the fasted state, maximum plasma concentrations are reached in 0.5 to 2 hours. While in the fed state, Cmax is reduced by 40%, Tmax is increased by one hour, and total absorption is unchanged.

    Route of Elimination

    Roflumilast is excreted 70% in the urine as roflumilast N-oxide.

    Volume of Distribution

    Roflumilast has a Vd of 2.9L/kg with a dose of 500mcg. Permeability of roflumilast across the blood-brain barrier appears to be poor in rat studies.

    Clearance

    ~9.6 L/hour.

    5.5 Metabolism/Metabolites

    Roflumilast is metabolized to roflumilast N-oxide, the active metabolite of roflumilast in humans, by CYP3A4 and CYP1A2.

    5.6 Biological Half-Life

    Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).

    5.7 Mechanism of Action

    Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor which, due to its selective inhibition of the PDE4 isoenzyme, has potential antiinflammatory and antimodulatory effects in the pulmonary system. It is thought that the increased levels of intracellular cyclic AMP are responsible for the therapeutic actions of Roflumilast.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"ROFLUMILAST","year":"2021","qtr":"Q1","strtotime":1610044200,"product":"ROFLUMILAST IH","address":"HETERO HOUSE, H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD-A.P.","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"PERRIGO COMPANY PLC","customerCountry":"ISRAEL","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"180321.4","totalValueFC":"1825.7","currency":"USD","unitRateINR":13352800,"date":"08-Jan-2021","totalValueINR":"133528","totalValueInUsd":"1825.7","indian_port":"HYDERABAD AIR","hs_no":"29333911","bill_no":"7764282","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE, H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD-A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"ROFLUMILAST","year":"2021","qtr":"Q2","strtotime":1618943400,"product":"ROFLUMILAST (GROUP:B SR NO:8119) (TAX IN","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"CANADA","quantity":"0.11","actualQuantity":"0.105","unit":"KGS","unitRateFc":"200000","totalValueFC":"20873.3","currency":"USD","unitRateINR":14800000,"date":"21-Apr-2021","totalValueINR":"1554000","totalValueInUsd":"20873.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1257100","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"ROFLUMILAST","year":"2021","qtr":"Q2","strtotime":1619029800,"product":"ROFLUMILAST (GROUP:B SR NO:8119) (TAX IN VOICE NO:1900215008 DT:09.04.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"CANADA","quantity":"0.11","actualQuantity":"0.105","unit":"KGS","unitRateFc":"205393.1","totalValueFC":"20871.3","currency":"USD","unitRateINR":14798571.428571429,"date":"22-Apr-2021","totalValueINR":"1553850","totalValueInUsd":"20871.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1283478","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1622485800,"product":"ROFLUMILAST (TAX INVOICE NO:1900215171 DT:24-05-2021) (GROUP:A","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"PERRIGO COMPANY PLC","customerCountry":"ISRAEL","quantity":"0.01","actualQuantity":"0.007","unit":"KGS","unitRateFc":"251040.9","totalValueFC":"1721.6","currency":"USD","unitRateINR":18087500,"date":"01-Jun-2021","totalValueINR":"126612.5","totalValueInUsd":"1721.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2146621","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648233000,"product":"339977 - ROFLUMILAST - NN4297","address":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU","city":"BANGALORE,KARNATAKA","supplier":"APOTEX INC","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"ADLI LOGISTICS","customerCountry":"CANADA","quantity":"0.16","actualQuantity":"0.159","unit":"KGS","unitRateFc":"79078.1","totalValueFC":"12411.5","currency":"USD","unitRateINR":5949685.5345911952,"date":"26-Mar-2022","totalValueINR":"946000","totalValueInUsd":"12411.5","indian_port":"BANGALORE ICD","hs_no":"29331999","bill_no":"9222536","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE ICD","supplierAddress":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648233000,"product":"339977 - ROFLUMILAST - NN4298","address":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU","city":"BANGALORE,KARNATAKA","supplier":"APOTEX INC","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"ADLI LOGISTICS","customerCountry":"CANADA","quantity":"0.17","actualQuantity":"0.169","unit":"KGS","unitRateFc":"79078.1","totalValueFC":"13185.6","currency":"USD","unitRateINR":5946745.5621301774,"date":"26-Mar-2022","totalValueINR":"1005000","totalValueInUsd":"13185.6","indian_port":"BANGALORE ICD","hs_no":"29331999","bill_no":"9222536","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE ICD","supplierAddress":"SITE NO.1,BOMMASANDRA INDL.AREA,IV ,PHASE,JIGANI LINK ROAD ANEKAL TALU, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674239400,"product":"ROFLUMILAST, REF NO. S_22_0429382, PRPN.","address":"TORRENT HOUSE, OFF ASHRAM ROAD,","city":"AHMEDABAD","supplier":"TORRENT PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"JASPER HOLZER,DEPUTY HEAD OF QC-","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"4","unit":"GMS","unitRateFc":"122.1","totalValueFC":"513.7","currency":"EUR","unitRateINR":10500,"date":"21-Jan-2023","totalValueINR":"42000","totalValueInUsd":"513.7","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"7145054","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"TORRENT HOUSE, OFF ASHRAM ROAD,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692210600,"product":"CS-O-11739 \/ ROFLUMILAST","address":"17 LOTUS BUSINESS PARKNEW LINK RD ANDHERI W","city":"MUMBAI","supplier":"CLEARSYNTH LABS LIMITED","supplierCountry":"INDIA","foreign_port":"HO CHI MINH CITY","customer":"ONLAB SCIENTIFIC CO LIMITED","customerCountry":"VIETNAM","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"240","totalValueFC":"236.6","currency":"USD","unitRateINR":19600.308000000001,"date":"17-Aug-2023","totalValueINR":"19600.308","totalValueInUsd":"236.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"17 LOTUS BUSINESS PARKNEW LINK RD ANDHERI W, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696617000,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TO THE ORDER OF,....;;","customerCountry":"CANADA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"100000","totalValueFC":"98679.2","currency":"USD","unitRateINR":8213000,"date":"07-Oct-2023","totalValueINR":"8213000","totalValueInUsd":"98679.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4469065","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699209000,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF.;;.;","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"180000","totalValueFC":"53259.9","currency":"USD","unitRateINR":14783333.333333334,"date":"06-Nov-2023","totalValueINR":"4435000","totalValueInUsd":"53259.9","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5158208","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699381800,"product":"ROFLUMILAST RC E( NET WT: 500 MG)","address":"H.NO.5-5-35\/196,PL.NO.41,SY.NO.389","city":"HYDERABAD","supplier":"SEINE PHARMA PRIVATE ","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"ISRAEL","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"4000","totalValueFC":"1993.5","currency":"USD","unitRateINR":332000,"date":"08-Nov-2023","totalValueINR":"166000","totalValueInUsd":"1993.5","indian_port":"Hyderabad Air","hs_no":"29309099","bill_no":"5217208","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO.5-5-35\/196,PL.NO.41,SY.NO.389, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720636200,"product":"ROFLUMILAST","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"PHARMAPIA CO. LTD","customerCountry":"REPUBLIC OF KOREA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"180000","totalValueFC":"53343.7","currency":"USD","unitRateINR":14863526.666666668,"date":"11-Jul-2024","totalValueINR":"4459058","totalValueInUsd":"53343.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2344233","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721241000,"product":"ROFLUMILAST USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEWARK, NJ","customer":"MSN PHARMACEUTICALS INC.","customerCountry":"UNITED STATES","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"153915","totalValueFC":"30324.7","currency":"USD","unitRateINR":12674360.5,"date":"18-Jul-2024","totalValueINR":"2534872.1","totalValueInUsd":"30324.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2504680","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
    08-Jan-2021
    18-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 250MCG

    USFDA APPLICATION NUMBER - 22522

    read-more

    DOSAGE - TABLET;ORAL - 500MCG

    USFDA APPLICATION NUMBER - 22522

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Granulation

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search